Evidence map›Paper›PMID 35013850›Full record

ReviewMolecular and cellular biochemistry2022

Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.

Foad Rommasi, Mohammad Javad Nasiri, Mehdi Mirsaeidi

Open access · bronzeAbstract readReview
In one paragraph

Review in Molecular and cellular biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Mucosal implications of oral Jak3-targeted drugs in COVID patients.Molecular medicine (Cambridge, Mass.) · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Drugs for COVID-19: An Update.Molecules (Basel, Switzerland) · 2022
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Foad RommasiFaculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. f.ramasi@mail.sbu.ac.ir.ORCID http://orcid.org/0000-0001-7189-170X
Mohammad Javad NasiriDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-3279-0671
Mehdi MirsaeidiDepartment of Pulmonary and Critical Care, Miller School of Medicine, University of Miami, Miami, FL, USA.ORCID http://orcid.org/0000-0001-5298-8442
Shahid Beheshti University · IRShahid Beheshti University of Medical Sciences · IRUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.

Indexed as

COVID-19 Drug TreatmentAntibodies, Monoclonal, HumanizedAntiviral AgentsAzetidinesCOVID-19DexamethasoneFamotidineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsImmunomodulating AgentsInfliximabInterleukin 1 Receptor Antagonist ProteinMelatoninPurinesPyrazolesSulfonamidesAntibodies, Monoclonal, HumanizedAntiviral AgentsAzetidinesbaricitinibDexamethasoneFamotidineHydroxymethylglutaryl-CoA Reductase InhibitorsImmunomodulating AgentsInfliximabInterleukin 1 Receptor Antagonist ProteinMelatoninPurinesPyrazolesSulfonamidestocilizumabCOVID-19 treatmentCytokine stormImmunosuppressive agentsInflammatory responsesPathophysiologySARS-CoV-2

Identifiers

PMID35013850
PMCPMC8747854
OpenAlexW4206093347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.